和黄医药6.08亿美元出售非核心合资企业股权,橙帆医药、克睿基因宣布完成数千万美元融资,迈科康生物宣布完成2亿元可转债融资

医药经济报
06 Jan

和黄医药以6.08亿美元出售非核心合资企业股权和黄医药(中国)有限公司宣布,达成两项协议以6.08亿美元 (人民币44.78亿元) 现金向上海金浦健服股权投资管理有限公司和上海医药集团股份有限公司出售其在上海和黄药业有限公司的45%的股权。据悉,上海和黄药业主要负责在中国生产、销售及分销其自有品牌处方药物,其主要产品为心血管疾病药物。上海和黄药业是由和黄医药和上海医药于2001年以50:50的比例...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10